The group from NYU School of Medicine will try to identify new drugs for the treatment of Chagas disease. At present, there are only two medicines available presenting significant toxicity and both are only effective against the early stages of this disease. The project will look into specific inhibitors of Trypanosoma cruzi infection of host cells. A recombinant Trypanosoma cruzi line expressing β-galactosidase will be used for screening the chemical library owned by GlaxoSmithKline (GSK). This assay is highly predictable and reproducible and meets the standards for high-throughput-screening.
The funds provided by the Tres Cantos Open Lab Foundation will support a visiting researcher to come to GSK’s R&D centre in Tres Cantos (Spain) to pursue their project as part of an integrated drug discovery team. For this purpose, GSK’s resources and facilities are necessary.
“This collaboration will bring new leads into the research community making efforts in this disease area, which could hopefully be transformed in better drug replacements to fight Chagas disease, an ailment that affects 10 million people” said Dr. Ana Rodríguez, associate professor of microbiology at NYU School of Medicine.
“Neglected tropical diseases continue to cause significant morbidity and mortality in the developing world. This is a good example of what a complementary effort by public groups and research based pharmaceutical companies can do to accelerate the process of discovery and drug optimisation” said Professor Sir Leszek Borysiewicz, Trustee and Chair of the Governing Board, Tres Cantos Open Lab Foundation (currently Vice-Chancellor of the University of Cambridge, previously Chief Executive of the Medical Research Council).
About the Tres Cantos Open Lab Foundation
The Tres Cantos Open Lab Foundation is focussed on providing funding and support for scientists, academics and institutions to develop and advance new ideas that could lead to new medicines to treat diseases of the developing world. Researchers are invited to submit projects for collaboration and funding, to be reviewed by the Foundation’s Governing Board and Trustees.
About NYU School of Medicine
NYU School of Medicine is one of the nation’s preeminent academic institutions dedicated to achieving world class medical educational excellence. For 170 years, NYU School of Medicine has trained thousands of physicians and scientists who have helped to shape the course of medical history and enrich the lives of countless people. An integral part of NYU Langone Medical Center, the School of Medicine at its core is committed to improving the human condition through medical education, scientific research and direct patient care. The School also maintains academic affiliations with area hospitals, including Bellevue Hospital, one of the nation’s finest municipal hospitals where its students, residents and faculty provide the clinical and emergency care to New York City’s diverse population, which enhances the scope and quality of their medical education and training. Additional information about the NYU School of Medicine is available at http://school.med.nyu.edu/.